Mali Salmon-Divon
Overview
Explore the profile of Mali Salmon-Divon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
5954
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tal O, Zahavi T, Sinberger L, Salmon-Divon M
PLoS One
. 2025 Jan;
20(1):e0317502.
PMID: 39821197
Objectives: Epithelial ovarian cancer is a significant contributor to cancer-related mortality in women, frequently recurring post-treatment, often accompanied by chemotherapy resistance. Dietary interventions have demonstrated influence on cancer progression; for...
2.
Salmon-Divon M, Meyuchas R, Shpilberg O, Okon E, Benhamida J, Yabe M, et al.
Leukemia
. 2024 Nov;
39(2):516-519.
PMID: 39516372
No abstract available.
3.
Kaczmarczyk L, Babele D, Levi N, Gunasekaran G, Salmon-Divon M, Gerlitz G
Eur J Cell Biol
. 2024 Sep;
103(4):151454.
PMID: 39232451
CTCF is a key factor in three-dimensional chromatin folding and transcriptional control that was found to affect cancer cell migration by a mechanism that is still poorly understood. To identify...
4.
Stemmer E, Zahavi T, Kellerman M, Sinberger L, Shrem G, Salmon-Divon M
Front Immunol
. 2024 Mar;
15:1353402.
PMID: 38510241
Background: Understanding the molecular pathogenesis of inflammatory bowel disease (IBD) has led to the discovery of new therapeutic targets that are more specific and effective. Our aim was to explore...
5.
Sinberger L, Zahavi T, Sonnenblick A, Salmon-Divon M
Sci Rep
. 2023 Nov;
13(1):20911.
PMID: 38017109
Up to 40% of luminal breast cancer patients carry activating mutations in the PIK3CA gene. PIK3CA mutations commonly co-occur with other mutations, but the implication of this co-occurrence may vary...
6.
Feldman D, Sinberger L, Salmon-Divon M, Ben-Dror J, Shachar S, Sonnenblick A
BMC Cancer
. 2023 Oct;
23(1):1031.
PMID: 37875892
Purpose: One-half of hormone receptor-positive (HR +) breast cancer (BC) patients have low expression of HER2 (HER2-low) and may benefit from trastuzumab deruxtecan (TDXd). This study aimed to identify parameters...
7.
Kumar S, Gahramanov V, Patel S, Yaglom J, Kaczmarczyk L, Alexandrov I, et al.
Int J Mol Sci
. 2023 May;
24(10).
PMID: 37240063
Resistance to chemotherapy is a leading cause of treatment failure. Drug resistance mechanisms involve mutations in specific proteins or changes in their expression levels. It is commonly understood that resistance...
8.
Fishov H, Muchtar E, Salmon-Divon M, Dispenzieri A, Zvida T, Schneider C, et al.
Cancer Med
. 2023 Jan;
12(7):8199-8210.
PMID: 36694297
Background: Noncoding RNAs such as microRNAs (miRNAs) have attracted attention as biological pathway regulators, which differ from chromosomal translocations and gene point mutations. Their involvement in the molecular mechanisms underlying...
9.
Raphael A, Salmon-Divon M, Epstein J, Zahavi T, Sonnenblick A, Shachar S
Genes (Basel)
. 2022 Oct;
13(10).
PMID: 36292649
This real-world cohort analysis assessed the efficacy of alpelisib and endocrine treatment (ET) combinations in a post-everolimus setting. Thirteen women who started alpelisib and ET at standard doses between 2018...
10.
Gahramanov V, Oz M, Aouizerat T, Rosenzweig T, Gorelick J, Drori E, et al.
Plants (Basel)
. 2022 Sep;
11(17).
PMID: 36079576
Medicinal properties of plants are usually identified based on knowledge of traditional medicine or using low-throughput screens for specific pharmacological activities. The former is very biased since it requires prior...